Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 13/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811133 | 0.92 | CCR3 (0.47) | CCR3DRD4GRM2KCNH2CCR2 | |
| SCHEMBL1808636 | 0.89 | CCR3 (0.44) | CCR3DRD4GRM2KCNH2CCR1 | |
| SCHEMBL1810623 | 0.89 | CCR3 (0.51) | CCR3DRD4GRM2KCNH2CCR2 | |
| SCHEMBL1810235 | 0.87 | DRD4 (0.44) | CCR3DRD4GRM2KCNH2CCR2 | |
| SCHEMBL1809999 | 0.87 | CCR3 (0.42) | CCR3DRD4GRM2KCNH2 | |
| SCHEMBL1807441 | 0.86 | DRD4 (0.44) | CCR3DRD4GRM2KCNH2NR1I2 | |
| SCHEMBL1810279 | 0.86 | CCR3 (0.44) | CCR3DRD4GRM2KCNH2CCR2 | |
| SCHEMBL1810432 | 0.85 | CCR3 (0.40) | CCR3DRD4CCR1 | |
| SCHEMBL1806562 | 0.85 | CCR3 (0.42) | CCR3DRD4 | |
| SCHEMBL1809736 | 0.85 | CCR3 (0.45) | CCR3DRD4GRM2KCNH2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CCR3 1/4885DRD4 768/4885GRM2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.